Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
revumenib + venetoclax
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Revuforj + venetoclax is an investigational combination regimen consisting of the oral menin-KMT2A inhibitor revumenib (Revuforj) and the oral BCL-2 inhibitor venetoclax (Venclexta). This combination is being evaluated, often alongside hypomethylating agents such as azacitidine or decitabine/cedazuridine, for the treatment of acute myeloid leukemia (AML) harboring specific genetic alterations, including KMT2A rearrangements (KMT2Ar), NPM1 mutations (NPM1m), or NUP98 rearrangements (NUP98r). By simultaneously targeting the menin-KMT2A interaction and BCL-2-mediated anti-apoptotic pathways, the combination exhibits synergistic antileukemic activity, promoting apoptosis and differentiation in leukemia cells. Clinical development is ongoing in both newly diagnosed and relapsed/refractory AML settings, including the Phase 3 EVOLVE-2 trial and the Phase 1/2 SAVE trial.
- Brand names
- Revuforj + VenclextaRevuforj + Venclyxto
- Other names
- Revuforj + venetoclaxSNDX-5613 + ABT-199SNDX-5613 + venetoclaxrevumenib + ABT-199revumenib + Venclextarevumenib + Venclyxto
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)KMT2AMCL1 (Myeloid cell leukemia sequence 1)MEN1 (Menin)BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on revumenib + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on revumenib + venetoclax.